Produção Nacional
Revisado por pares
Expanding Indications for Recombinant Human TSH in Thyroid Cancer
2008; Mary Ann Liebert, Inc.; Volume: 18; Issue: 7 Linguagem: Inglês
10.1089/thy.2008.0162
ISSN1557-9077
AutoresBryan R. Haugen, David S. Cooper, Charles H. Emerson, Markus Luster, Rui M. B. Maciel, Rosa Paula M. Biscolla, Ernest L. Mazzaferri, Geraldo Medeiros‐Neto, Christoph Reiners, Richard J. Robbins, Bruce G. Robinson, Martin Schlumberger, Shunichi Yamashita, Furio Pacini,
Tópico(s)Head and Neck Anomalies
ResumoThyroidVol. 18, No. 7 Editorials and CommentaryExpanding Indications for Recombinant Human TSH in Thyroid CancerBryan R. Haugen, David S. Cooper, Charles H. Emerson, Markus Luster, Rui M.B. Maciel, Rosa P.M. Biscolla, Ernest L. Mazzaferri, Geraldo Medeiros-Neto, Christoph Reiners, Richard J. Robbins, Bruce G. Robinson, Martin Schlumberger, Shunichi Yamashita, and Furio PaciniBryan R. HaugenSearch for more papers by this author, David S. CooperSearch for more papers by this author, Charles H. EmersonSearch for more papers by this author, Markus LusterSearch for more papers by this author, Rui M.B. MacielSearch for more papers by this author, Rosa P.M. BiscollaSearch for more papers by this author, Ernest L. MazzaferriSearch for more papers by this author, Geraldo Medeiros-NetoSearch for more papers by this author, Christoph ReinersSearch for more papers by this author, Richard J. RobbinsSearch for more papers by this author, Bruce G. RobinsonSearch for more papers by this author, Martin SchlumbergerSearch for more papers by this author, Shunichi YamashitaSearch for more papers by this author, and Furio PaciniSearch for more papers by this authorPublished Online:16 Jul 2008https://doi.org/10.1089/thy.2008.0162AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited ByMetastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for 131I Administration2 March 2022 | Journal of the Endocrine Society, Vol. 6, No. 5Thyroid Uptake and Effective Half-Life of Radioiodine in Thyroid Cancer Patients at Radioiodine Therapy and Follow-Up Whole-Body Scintigraphy Either in Hypothyroidism or Under rhTSH12 October 2018 | Journal of Nuclear Medicine, Vol. 60, No. 5Surveillance Strategies After Initial Treatment of Differentiated Thyroid Cancer25 June 2017Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer26 September 2016 | Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 76, No. 8The Nuclear Medicine Therapy Care Coordination ServiceAcademic Radiology, Vol. 22, No. 6Effects of Recombinant Human Thyrotropin Administration on 24-Hour Arterial Pressure in Female Undergoing Evaluation for Differentiated Thyroid CancerInternational Journal of Endocrinology, Vol. 2014Patología tiroideaMedicine - Programa de Formación Médica Continuada Acreditado, Vol. 11, No. 14Recombinant Human Thyroid Stimulating Hormone in Thyroid Remnant Ablation With 1.1 GBq 131Iodine in Low-Risk PatientsAmerican Journal of Clinical Oncology, Vol. 35, No. 2Evaluation of whole-body retention of iodine-131 (131I) after postoperative remnant ablation for differentiated thyroid carcinoma – thyroxine withdrawal versus rhTSH administration: A retrospective comparison14 December 2011 | Oncology Letters, Vol. 3, No. 3Diagnostic Value of Recombinant Human Thyrotropin–Stimulated 123I Whole-Body Scintigraphy in the Follow-Up of Patients With Differentiated Thyroid CancerClinical Nuclear Medicine, Vol. 37, No. 3When Will Thyrotropin Receptor Antagonists and Inverse Thyrotropin Receptor Agonists Become Available for Clinical Use? Charles H. Emerson2 August 2011 | Thyroid, Vol. 21, No. 8Differentiated thyroid cancer: an updateCurrent Opinion in Oncology, Vol. 23, No. 1To Stimulate or Withdraw? A Cost-Utility Analysis of Recombinant Human Thyrotropin Versus Thyroxine Withdrawal for Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer in the United StatesThe Journal of Clinical Endocrinology & Metabolism, Vol. 95, No. 4Update on Recent Developments in the Therapy of Differentiated Thyroid CancerSeminars in Nuclear Medicine, Vol. 40, No. 2Recombinant Human TSH: The Argentinean Experience Fabián Pitoia and Hugo Niepomniszcze7 July 2009 | Thyroid, Vol. 19, No. 7What role for recombinant human TSH in the treatment of metastatic thyroid cancer?20 January 2009 | European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 6Reply: A Proposition for the Use of Radioiodine in WDTC Management21 January 2009 | Journal of Nuclear Medicine, Vol. 50, No. 2 Volume 18Issue 7Jul 2008 InformationCopyright 2008, Mary Ann Liebert, Inc.To cite this article:Bryan R. Haugen, David S. Cooper, Charles H. Emerson, Markus Luster, Rui M.B. Maciel, Rosa P.M. Biscolla, Ernest L. Mazzaferri, Geraldo Medeiros-Neto, Christoph Reiners, Richard J. Robbins, Bruce G. Robinson, Martin Schlumberger, Shunichi Yamashita, and Furio Pacini.Expanding Indications for Recombinant Human TSH in Thyroid Cancer.Thyroid.Jul 2008.687-694.http://doi.org/10.1089/thy.2008.0162Published in Volume: 18 Issue 7: July 16, 2008PDF download
Referência(s)